BioVaxys Completes Third Tranche of Private Placement and Settles Debt

BioVaxys Technology ( (TSE:BIOV) ) has shared an update.

BioVaxys Technology Corp. has completed the third tranche of its private placement, raising $537,500 through the issuance of 10,750,000 units at $0.05 per unit. Each unit includes a common share and a warrant convertible into an additional share at $0.15 until January 10, 2027. The proceeds will be used for working capital, and no finder’s fees were incurred. The company also issued 5,000,000 shares at $0.10 per share to settle $500,000 of debt with an external consultant. This financial maneuvering is expected to support BioVaxys’s ongoing operations and enhance its market positioning as it continues to develop its immunotherapy platforms.

More about BioVaxys Technology

BioVaxys Technology Corp., based in British Columbia, Canada, is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies using its DPX™ technology platform and HapTenix© ‘neoantigen’ tumor cell construct platform. These platforms are designed to treat cancers, infectious diseases, and other immunological conditions by inducing targeted, long-lasting immune responses.

YTD Price Performance: -10.0%

Average Trading Volume: 514,112

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $10.68M

For an in-depth examination of BIOV stock, go to TipRanks’ Stock Analysis page.